⚠ Evidence warning: Clinical trials or other evidence do not support the claims that glutathione depletion is a unifying feature of nearly every chronic disease, that repletion is likely to benefit each listed condition, that intravenous glutathione helps autoimmune disease and chronic infection, and that GlyNAC restores more glutathione than N-acetylcysteine alone. This page keeps it as a report of what people, websites or other media say.
Glutathione — The Master Antioxidant
Glutathione (reduced glutathione, GSH) is a small tripeptide — just gamma-glutamate, cysteine, and glycine — but it is the single most important antioxidant molecule in human cells. Intracellular concentration runs 3-10 millimolar, well above most other antioxidants inside cells (Vitamin C reaches about 1-5 mM in the adrenal medulla and brain, its highest tissues, and far less elsewhere). It is the substrate for glutathione peroxidase that neutralizes hydrogen peroxide and lipid peroxides, the substrate for the glutathione-S-transferase family that conjugates electrophilic toxins for excretion, the maintainer of protein and Vitamin C and E in their reduced forms, the cysteine reservoir for the liver, and the upstream control point for cellular redox status. Glutathione depletion is now recognized as a unifying feature of aging and nearly every chronic disease. This deep-dive walks through the biochemistry, the validated lab tests for status, the disputed oral-glutathione bioavailability story, and the supplements (liposomal, S-acetyl, N-acetylcysteine (NAC) plus glycine) that actually raise tissue levels.
Table of Contents
- What Glutathione Is and Why It Dominates Cellular Antioxidant Defense
- Synthesis: The Two-Step Adenosine Triphosphate-Dependent Pathway
- The GSH/GSSG Redox Couple as Cellular Status Indicator
- Enzymatic Functions: GPx, GST, Glutaredoxin
- Detoxification: Phase II Conjugation and the Liver
- The Oral Glutathione Bioavailability Problem
- Supplements That Actually Raise Tissue Glutathione
- Conditions Associated with Glutathione Depletion
- Lab Testing for Glutathione Status
- Cautions and Drug Interactions
- Key Research Papers
- Connections
- Featured Videos
What Glutathione Is and Why It Dominates Cellular Antioxidant Defense
Glutathione is a tripeptide composed of three amino acids joined in an unusual way: gamma-glutamate — cysteine — glycine. The "gamma" linkage between glutamate and cysteine (using the gamma-carboxyl group of glutamate rather than the standard alpha-carboxyl) makes glutathione resistant to digestion by most peptidases — an evolutionary feature that protects intracellular glutathione from rapid breakdown but also creates the oral-bioavailability problem discussed below.
The functional group that does the antioxidant work is the thiol (-SH) group on the cysteine residue. This thiol readily donates an electron to neutralize reactive oxygen species and reactive electrophiles. When two glutathione molecules each donate an electron, they form a disulfide bond between their cysteine sulfurs, producing oxidized glutathione (GSSG). The GSSG is then recycled back to two reduced glutathione molecules by glutathione reductase using reduced nicotinamide adenine dinucleotide phosphate (NADPH) (generated by the pentose phosphate pathway) as the electron donor.
Three properties make glutathione the dominant cellular antioxidant:
- Sheer concentration — 3-10 mM intracellular, with liver hepatocytes at the top of that range. By comparison, intracellular Vitamin C is ~1-5 mM in adrenal medulla and brain (the highest tissues) and far less elsewhere; Vitamin E is in the membrane micromolar range. Glutathione's mass abundance means it can absorb large oxidant loads without depletion.
- Versatile chemistry — the thiol can directly reduce peroxides (with GPx), conjugate electrophiles (with GST), reduce disulfides on oxidatively damaged proteins (glutaredoxin system), and recycle oxidized Vitamin C and Vitamin E back to their active reduced forms. No other antioxidant has this functional breadth.
- Regenerable — unlike Vitamin C and E, which the body cannot synthesize de novo, glutathione is synthesized inside every cell continuously, and the oxidized form is recycled rather than excreted.
This makes glutathione the cellular currency of antioxidant capacity. When researchers talk about "the master antioxidant," this is not marketing — it is biochemistry.
Synthesis: The Two-Step Adenosine Triphosphate-Dependent Pathway
Glutathione is synthesized in two sequential adenosine triphosphate-dependent enzyme steps:
- Step 1 (rate-limiting): gamma-glutamyl cysteine ligase (GCL, formerly called gamma-glutamylcysteine synthetase) joins glutamate to cysteine, forming gamma-glutamyl-cysteine. This step consumes ATP. GCL is composed of a catalytic subunit (GCLC) and a modifier subunit (GCLM), both transcriptionally regulated by Nrf2. Cysteine is the rate-limiting substrate in most physiological conditions — cellular cysteine availability determines synthesis rate, which is why N-acetylcysteine is the most effective glutathione-boosting supplement.
- Step 2: glutathione synthetase (GSS) adds glycine to the dipeptide, completing the tripeptide. This step also consumes ATP. GSS is not normally rate-limiting except in the rare inborn error glutathione synthetase deficiency.
The pathway requires three precursor amino acids, four cofactors, and energy:
- Cysteine — the limiting substrate. Endogenously generated from methionine through the transsulfuration pathway (a B6-dependent process), or obtained directly from dietary protein. Cysteine is the rarest of the three precursors because its free form is unstable and rapidly oxidized in plasma.
- Glutamate — abundantly available from dietary protein and de novo synthesis.
- Glycine — previously assumed adequate but recent work by Sekhar at Baylor shows glycine is co-rate-limiting in older adults and many chronic disease states. The GlyNAC supplementation studies (glycine + N-acetylcysteine) report restored glutathione in older adults. They are also described as restoring more than N-acetylcysteine alone, although the GlyNAC trials read for this page have no N-acetylcysteine-alone group.
- Selenium — required for glutathione peroxidase activity (the enzyme is a selenoprotein with selenocysteine at the active site). Selenium deficiency cripples glutathione function even when glutathione concentration is adequate.
- Reduced nicotinamide adenine dinucleotide phosphate — required to recycle GSSG back to reduced glutathione by glutathione reductase. Reduced nicotinamide adenine dinucleotide phosphate is generated by the pentose phosphate pathway (glucose-6-phosphate dehydrogenase (G6PD) enzyme); glucose-6-phosphate dehydrogenase deficiency causes hemolytic anemia precisely because red blood cells cannot regenerate glutathione.
- Vitamins B2 (FAD cofactor for glutathione reductase) and B6 (transsulfuration pathway) — required for the broader pathway.
Practical implication: because the pathway draws on all of these, supplementation strategies aimed at glutathione are described as covering cysteine, glycine, selenium, and adequate B-vitamin status — not just oral glutathione capsules.
The GSH/GSSG Redox Couple as Cellular Status Indicator
The ratio of reduced to oxidized glutathione (GSH/GSSG) is the most accurate single biochemical indicator of cellular redox status. In healthy resting cells the ratio is approximately 100:1 (overwhelmingly reduced). Under oxidative stress the ratio drops — first to 50:1, then 25:1, and in severe oxidative stress to 10:1 or below.
The redox potential of the GSH/GSSG couple can be calculated from the Nernst equation and the measured concentrations. In healthy cytoplasm the redox potential is approximately -240 to -250 mV. As GSSG accumulates this becomes less negative (toward -200 mV in oxidatively stressed cells, -170 mV in apoptotic cells). The potential appears to track the state of the cell: a 2001 review by Schafer and Buettner gives approximately -240 mV for cells that are multiplying, approximately -200 mV for cells that are differentiating (taking on a specialized form), and approximately -170 mV for apoptosis (programmed cell death). Glutathione is therefore not just a buffer absorbing reactive oxygen species (ROS) — it is a redox signal that the cell reads to decide whether to grow, differentiate, or die.
Different organelles maintain different redox potentials. The endoplasmic reticulum is intentionally more oxidizing than the cytoplasm (around -180 mV) because disulfide bond formation in nascent proteins requires an oxidizing environment. Mitochondrial matrix is approximately -280 mV (more reducing than cytoplasm, supporting electron transport chain function). The nucleus tracks closely with cytoplasm. When measuring glutathione in research or clinical settings, the compartment matters — whole-cell glutathione obscures these important compartmental differences.
Enzymatic Functions: GPx, GST, Glutaredoxin
Glutathione almost never acts alone — it is the substrate for three major enzyme families that direct its antioxidant chemistry to specific targets.
Glutathione peroxidases (GPx, 8 family members) — selenoproteins that use glutathione to reduce hydrogen peroxide to water, and lipid hydroperoxides to their corresponding alcohols. GPx1 is the major cytosolic form, GPx4 is specialized for membrane lipid peroxides (and is the enzyme inhibited in ferroptosis cell death), GPx2 is gut-specific, GPx3 is plasma-secreted. Selenium deficiency impairs all of them — this is why selenium and glutathione status must be considered together.
Glutathione-S-transferases (GST, 6 cytosolic families plus microsomal forms) — conjugate glutathione to electrophilic molecules (drug metabolites, environmental toxins, carcinogens). The glutathione conjugate is then processed through the mercapturic acid pathway and excreted in urine. This is the dominant Phase II detoxification mechanism for compounds like acetaminophen reactive metabolite NAPQI, naphthalene, vinyl chloride, ethylene oxide, and hundreds of others. GST polymorphisms (GSTM1 null, GSTT1 null) are common (40-60% of populations) and associated with altered chemical sensitivity and cancer risk.
Glutaredoxin (Grx) system — uses glutathione to reduce protein disulfides that form on oxidatively damaged proteins, restoring native protein structure. Especially important in protein folding quality control and in repairing oxidatively damaged thioredoxin (which has its own reduced nicotinamide adenine dinucleotide phosphate-dependent reduction system in parallel).
Recycling of other antioxidants — glutathione directly reduces the tocopheryl radical (oxidized Vitamin E) back to Vitamin E, and reduces the ascorbyl radical (oxidized Vitamin C) back to Vitamin C. This is why glutathione, Vitamin C, and Vitamin E are inseparable as a functional network rather than independent antioxidants.
Detoxification: Phase II Conjugation and the Liver
The liver is the body's primary detoxification organ and has the highest glutathione concentration of any tissue (~8-10 mM in healthy hepatocytes). Liver detoxification proceeds in three phases:
- Phase I (cytochrome P450 oxidation) — CYP450 enzymes add oxygen or hydroxyl groups to lipophilic xenobiotics, making them more water-soluble but often more reactive (sometimes more toxic, as with acetaminophen).
- Phase II conjugation — the reactive Phase I product is conjugated to a polar carrier molecule. The main pathways are glucuronidation (UGT enzymes), sulfation (SULT enzymes), glycine conjugation, methylation (with S-adenosylmethionine, SAMe), acetylation (NAT enzymes), and glutathione conjugation (GST enzymes). The glutathione conjugate is then processed through the mercapturic acid pathway.
- Phase III excretion — ABC transporters pump the conjugated metabolite into bile (for fecal excretion) or back to plasma for urinary excretion.
The classic clinical example is acetaminophen overdose. Acetaminophen is normally cleared 90% by glucuronidation and sulfation; only 5-10% goes through cytochrome P450 2E1 (CYP2E1), generating the reactive intermediate NAPQI which is immediately quenched by glutathione conjugation. In overdose, glucuronidation and sulfation saturate, more acetaminophen flows through CYP2E1, NAPQI production exceeds glutathione capacity, hepatic glutathione drops below 30% of normal, free NAPQI then arylates hepatocyte proteins, and centrilobular necrosis ensues. The antidote is N-acetylcysteine given to replenish hepatic glutathione — the same N-acetylcysteine discussed in the N-acetylcysteine deep-dive page.
Chronic environmental and dietary toxicant load (heavy metals, pesticides, industrial chemicals, mycotoxins) similarly draws on glutathione. Individuals with high toxicant exposure or impaired detoxification (GST polymorphisms, methylenetetrahydrofolate reductase (MTHFR) variants affecting B-vitamin status) deplete glutathione faster and benefit more from supportive supplementation.
The Oral Glutathione Bioavailability Problem
For decades the supplement industry has sold oral glutathione capsules as a way to raise tissue glutathione. The biochemistry has always been skeptical: oral glutathione faces three problems.
- Digestive degradation — gamma-glutamyl transpeptidase in the intestinal brush border cleaves glutathione into its constituent amino acids before absorption. Most ingested glutathione never enters the bloodstream intact.
- First-pass hepatic extraction — any glutathione that does survive digestion is largely extracted by the liver on first pass through the portal circulation.
- Cell membrane impermeability — even if glutathione reached peripheral tissues intact, the cell membrane has no efficient glutathione transporter for uptake. Cells synthesize glutathione intracellularly rather than importing it.
The Allen and Bradley 2011 randomized, double-blind trial (40 healthy adults, 500 mg twice daily for 4 weeks) found that conventional oral glutathione did not change glutathione measured in red blood cells, or markers of oxidative stress. A 2015 randomized, double-blind trial by Richie et al. (54 non-smoking adults, 250 or 1,000 mg/day for 6 months) reported the opposite: blood glutathione rose at 1, 3 and 6 months at both doses. At 6 months the high dose gave increases of 30-35% in red blood cells, plasma and lymphocytes and 260% in cells from the inside of the cheek; the low dose gave 17% in blood and 29% in red blood cells. Natural killer cell activity more than doubled on the high dose at 3 months, and levels returned to baseline after a 1-month washout. The authors concluded that daily glutathione "was effective at increasing body compartment stores." One explanation offered is that the rise comes from cysteine released after digestion rather than from intact glutathione; neither abstract tests this.
So the two randomized trials disagree, at different lengths and doses. A common view, which neither trial tests, is that oral conventional glutathione is, at best, an expensive way to deliver cysteine to the liver. The next section lists the other approaches in use.
Supplements That Actually Raise Tissue Glutathione
The interventions reported to raise tissue glutathione, in this page's order (not a strict ranking, since the studies differ in design and size):
- N-acetylcysteine 600-1800 mg/day — supplies the rate-limiting cysteine precursor. Approved as the prescription drug acetylcysteine for acetaminophen overdose, where it demonstrably restores depleted hepatic glutathione. Best-studied supplemental approach. See the N-acetylcysteine deep-dive.
- GlyNAC (glycine + N-acetylcysteine combination, often 100 mg/kg each per day) — Sekhar's Baylor group showed glycine is co-rate-limiting with cysteine in older adults. Their 2021 pilot was open-label with no placebo (36 weeks; 8 older and 8 young adults, the older adults taking GlyNAC for 24 weeks) and reported restoration of erythrocyte glutathione to youthful levels, plus improvements in mitochondrial function, insulin sensitivity, and walking speed; the benefits declined after 12 weeks off GlyNAC. A later placebo-controlled trial from the same group randomized 24 older adults to GlyNAC or alanine for 16 weeks and reported that glutathione deficiency, oxidative stress and physical function improved on GlyNAC and not on placebo. A trial from a different group in 114 healthy older volunteers (2 weeks, up to 7.2 g a day) found no rise in total glutathione (903.5 mg/L on placebo vs 959.6 mg/L on 7.2 g, p = 0.278), except in a post-hoc subset with high oxidative stress and low starting glutathione on the medium and high doses.
- Liposomal glutathione (typically 500-1000 mg/day) — encapsulating glutathione in phospholipid liposomes protects it through digestion. Sinha et al. 2018, a 1-month pilot study in 12 healthy adults at 500 and 1,000 mg/day, reported that liposomal glutathione raised blood glutathione and natural killer (NK) cell function, with the largest rises after 2 weeks. More expensive than N-acetylcysteine; it is used as an alternative when N-acetylcysteine produces side effects or for severe depletion states.
- S-acetyl-glutathione — the acetyl group protects the thiol from oxidation during digestion. Limited but suggestive evidence for improved bioavailability over conventional glutathione. Still more expensive than N-acetylcysteine for unclear added benefit.
- Whey protein (10-40 g/day) — rich in cysteine-containing peptides (especially undenatured whey, preserving the disulfide bonds). Multiple studies show measurable increases in lymphocyte glutathione.
- Intravenous glutathione (600-2400 mg per session) — bypasses absorption entirely. Used investigationally for Parkinson's disease (an open-label study of 9 patients with no control group, Sechi 1996, reported a 42% decline in disability; a randomized placebo-controlled pilot, Hauser 2009, found no significant difference); also used in some integrative-medicine practices for autoimmune and chronic infection. Studies are small; insurance does not cover.
- Sulforaphane (10-40 mg/day from broccoli sprout extract) — activates Nrf2, which transcribes the GCLC and GCLM genes that produce gamma-glutamyl cysteine ligase, increasing endogenous synthesis capacity. Indirect but durable mechanism.
- Alpha-lipoic acid (300-600 mg/day) — regenerates oxidized glutathione and other antioxidants. Also chelates metal ions that catalyze reactive oxygen species production.
Conditions Associated with Glutathione Depletion
Glutathione depletion is documented in essentially every chronic disease state that has been studied. The relevant clinical contexts where repletion is likely to provide benefit:
- Aging — erythrocyte glutathione declines steadily after age 60, reaching approximately 40-50% of youthful levels by age 80. The Sekhar GlyNAC work specifically targets this age-related decline.
- Liver disease — hepatitis (viral, alcoholic, non-alcoholic fatty liver disease, NAFLD), cirrhosis. The U.S. Food and Drug Administration label for acetylcysteine injection lists use after a potentially liver-damaging amount of acetaminophen, not non-acetaminophen acute liver failure. In a randomized, double-blind trial of 173 patients with non-acetaminophen acute liver failure (Lee 2009), overall survival at 3 weeks was 70% on N-acetylcysteine vs 66% on placebo (not significant). Survival without a transplant was 40% vs 27%, a gain confined to early coma grades I-II (52% vs 30%) and absent in grades III-IV (9% vs 22%).
- Parkinson's disease — substantia nigra glutathione is reduced in early Parkinson's, possibly before dopaminergic neuron loss is detectable clinically. Intravenous (IV) glutathione: an open-label study of 9 patients with no control group (Sechi 1996) reported a 42% decline in disability; a randomized, double-blind, placebo-controlled pilot of 21 subjects (Hauser 2009, 1,400 mg three times a week for 4 weeks) found no significant differences (2.8 units more improvement, P = 0.32), and its authors said a mild symptomatic effect remained possible and needed a larger study.
- Human immunodeficiency virus (HIV) infection — glutathione depletion correlates with disease progression; supplementation studies show modest immune benefit.
- Sickle cell disease and glucose-6-phosphate dehydrogenase deficiency — red blood cells have impaired glutathione recycling, contributing to hemolysis.
- Severe burns, sepsis, and major surgery — massive acute glutathione depletion from the inflammatory and oxidant burden.
- Type 2 diabetes — chronic hyperglycemia depletes glutathione through several mechanisms including increased advanced glycation end-product (AGE) formation.
- Chronic obstructive pulmonary disease — cigarette smoke depletes airway glutathione; the N-acetylcysteine trials on flare-ups (exacerbations) disagree. BRONCUS (523 patients, 600 mg daily, 3 years) found no difference, 1.25 vs 1.29 a year (hazard ratio 0.99, p=0.85), and concluded N-acetylcysteine was ineffective at preventing them. PANTHEON (1,006 patients in China with moderate-to-severe disease, 600 mg twice daily, 1 year) found fewer, 1.16 vs 1.49 per patient-year (risk ratio 0.78).
- Autism spectrum disorder — observational studies consistently show reduced plasma glutathione and altered methylation. Small trials of N-acetylcysteine have shown modest behavioral benefits.
- Heavy metal exposure — mercury, cadmium, arsenic, and lead all draw on glutathione for conjugation and excretion.
- Acetaminophen overdose — the most acute and quantitatively dramatic glutathione depletion in clinical medicine.
Lab Testing for Glutathione Status
Several lab tests can characterize glutathione status, in order of clinical utility:
- Erythrocyte (red blood cell) glutathione — the most clinically used measurement. A normal range of approximately 800-1500 micromol per liter of red cells is given here without a cited source; in one small study (Sekhar 2011) younger adults averaged 2.08 mmol per liter of red cells (about 2,080 micromol) and elderly adults 1.12 mmol. Reflects glutathione synthesis capacity over the preceding 120 days (red cell lifespan).
- GSH/GSSG ratio in plasma or erythrocytes — provides redox status independent of absolute concentration. More technically demanding because GSSG must be stabilized to prevent further oxidation during sample handling.
- Lymphocyte glutathione — useful in immune-related contexts (human immunodeficiency virus, autoimmunity).
- Whole-blood glutathione — less informative than erythrocyte-specific.
- Functional measures — F2-isoprostanes (lipid peroxidation marker), 8-OHdG (DNA oxidation marker), glutathione peroxidase activity, glutathione-S-transferase activity. These provide indirect evidence of glutathione adequacy.
- Genetic testing — GSTM1 null, GSTT1 null, GSTP1 polymorphisms, GPX1 Pro198Leu variant. Identify individuals with impaired glutathione function.
Most commercial labs offer erythrocyte glutathione as a send-out test. Functional / specialty labs offer the GSH/GSSG ratio and oxidative stress marker panels.
Cautions and Drug Interactions
- N-acetylcysteine + nitroglycerin — potentiates the hypotensive and headache effects of nitroglycerin (N-acetylcysteine restores S-nitrosothiol metabolism); the concern applies to people taking nitrates.
- Glutathione and chemotherapy — theoretical concern that boosting glutathione during chemotherapy could blunt the oxidative-stress-mediated antitumor effect of some agents (cisplatin, doxorubicin). Oncologists are described as generally discouraging high-dose antioxidants during active chemo, and practitioners describe repletion after chemo completes.
- Asthma and oral N-acetylcysteine — oral N-acetylcysteine is well-tolerated, but nebulized N-acetylcysteine can trigger bronchospasm in susceptible patients — it is described as given together with a bronchodilator.
- Nebulized glutathione and asthma — breathing in nebulized glutathione (600 mg) caused major airway narrowing in a randomized, double-blind, placebo-controlled crossover study of 8 people with mild asthma: the air blown out in one second fell 19% vs 1% on placebo, with cough in 4 and breathlessness in 3. The fall tracked with sensitivity to metabisulfite, the authors point to sulfite formation, and nebulized salbutamol given beforehand blocked it.
- Sulfite sensitivity — glutathione metabolites include sulfites; rare individuals with sulfite-driven asthma may react to high-dose glutathione or N-acetylcysteine.
- Pregnancy — N-acetylcysteine has been used in pregnancy for acetaminophen overdose without harm to the fetus; routine high-dose supplementation outside that indication has limited data and is not routine practice.
- Bipolar disorder and N-acetylcysteine — multiple trials show benefit for bipolar depression. In one randomized, double-blind trial (Berk 2008: 75 patients, 1 g twice daily added to usual medication, 24 weeks), the depression scale improved by 8.05 points more than on placebo, with no effect on time to a mood episode, and the improvements were lost after a 4-week washout. The only signal of concern is occasional reports of mania in initial weeks of treatment in bipolar I patients — gradual introduction under psychiatric supervision is how it is described as being handled.
- Sulfur smell — high-dose N-acetylcysteine has a distinct sulfur taste / smell that some people find unpleasant; capsules taken with food and water minimize this.
- Glutathione is not a heavy-metal antidote — despite supplement marketing, formal chelation of toxic metals (lead, mercury, arsenic) requires specific chelating agents (DMSA, EDTA, DMPS) under medical supervision. Glutathione contributes to physiological metal handling but is not a substitute for chelation in true metal toxicity.
Key Research Papers
- Meister A, Anderson ME (1983). Glutathione. Annual Review of Biochemistry. — PubMed
- Lu SC (2013). Glutathione synthesis. Biochimica et Biophysica Acta. — PubMed
- Sekhar RV et al. (2011). Deficient synthesis of glutathione underlies oxidative stress in aging and can be corrected by dietary cysteine and glycine supplementation. American Journal of Clinical Nutrition. — PubMed PMID: 21795440
- Kumar P et al. (2021). Glycine and N-acetylcysteine (GlyNAC) supplementation in older adults improves glutathione deficiency, oxidative stress, mitochondrial dysfunction, inflammation, insulin resistance, endothelial dysfunction, genotoxicity, muscle strength, and cognition: results of a pilot clinical trial. Clinical and Translational Medicine. — PubMed PMID: 33783984
- Sinha R et al. (2018). Oral supplementation with liposomal glutathione elevates body stores of glutathione and markers of immune function. European Journal of Clinical Nutrition. — PubMed PMID: 28853742
- Allen J, Bradley RD (2011). Effects of oral glutathione supplementation on systemic oxidative stress biomarkers in human volunteers. Journal of Alternative and Complementary Medicine. — PubMed PMID: 21875351
- Richie JP Jr et al. (2015). Randomized controlled trial of oral glutathione supplementation on body stores of glutathione. European Journal of Nutrition. — PubMed PMID: 24791752
- Sechi G et al. (1996). Reduced intravenous glutathione in the treatment of early Parkinson's disease. Progress in Neuro-Psychopharmacology and Biological Psychiatry. — PubMed PMID: 8938817
- Prescott LF et al. (1979). Intravenous N-acetylcysteine: the treatment of choice for paracetamol poisoning. BMJ. — PubMed PMID: 519312
- Forman HJ, Zhang H, Rinna A (2009). Glutathione: overview of its protective roles, measurement, and biosynthesis. Molecular Aspects of Medicine. — PubMed
- Townsend DM, Tew KD, Tapiero H (2003). The importance of glutathione in human disease. Biomedicine & Pharmacotherapy. — PubMed
- Schmitt B, Vicenzi M, Garrel C, Denis FM (2015). Effects of N-acetylcysteine, oral glutathione (GSH) and a novel sublingual form of GSH on oxidative stress markers: a comparative crossover study. Redox Biology. — PubMed PMID: 26262996
- Schafer FQ, Buettner GR (2001). Redox environment of the cell as viewed through the redox state of the glutathione disulfide/glutathione couple. Free Radical Biology & Medicine. — PubMed PMID: 11368918
- Lee WM, Hynan LS, Rossaro L, Fontana RJ, Stravitz RT, Larson AM, Davern TJ 2nd, Murray NG, McCashland T, Reisch JS, Robuck PR; Acute Liver Failure Study Group (2009). Intravenous N-acetylcysteine improves transplant-free survival in early stage non-acetaminophen acute liver failure. Gastroenterology. — PubMed PMID: 19524577
- Decramer M, Rutten-van Mölken M, Dekhuijzen PN, Troosters T, van Herwaarden C, Pellegrino R, van Schayck CP, Olivieri D, Del Donno M, De Backer W, Lankhorst I, Ardia A (2005). Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomised placebo-controlled trial. Lancet. — PubMed PMID: 15866309
- Zheng JP, Wen FQ, Bai CX, Wan HY, Kang J, Chen P, Yao WZ, Ma LJ, Li X, Raiteri L, Sardina M, Gao Y, Wang BS, Zhong NS; PANTHEON study group (2014). Twice daily N-acetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): a randomised, double-blind placebo-controlled trial. Lancet Respiratory Medicine. — PubMed PMID: 24621680
- Hauser RA, Lyons KE, McClain T, Carter S, Perlmutter D (2009). Randomized, double-blind, pilot evaluation of intravenous glutathione in Parkinson's disease. Movement Disorders. — PubMed PMID: 19230029
- Kumar P, Liu C, Suliburk J, Hsu JW, Muthupillai R, Jahoor F, Minard CG, Taffet GE, Sekhar RV (2023). Supplementing glycine and N-acetylcysteine (GlyNAC) in older adults improves glutathione deficiency, oxidative stress, mitochondrial dysfunction, inflammation, physical function, and aging hallmarks: a randomized clinical trial. Journals of Gerontology Series A: Biological Sciences and Medical Sciences. — PubMed PMID: 35975308
- Lizzo G, Migliavacca E, Lamers D, Frézal A, Corthesy J, Vinyes-Parès G, Bosco N, Karagounis LG, Hövelmann U, Heise T, von Eynatten M, Gut P (2022). A randomized controlled clinical trial in healthy older adults to determine efficacy of glycine and N-acetylcysteine supplementation on glutathione redox status and oxidative damage. Frontiers in Aging. — PubMed PMID: 35821844
- Marrades RM, Roca J, Barberà JA, de Jover L, MacNee W, Rodriguez-Roisin R (1997). Nebulized glutathione induces bronchoconstriction in patients with mild asthma. American Journal of Respiratory and Critical Care Medicine. — PubMed PMID: 9279219
- Berk M, Copolov DL, Dean O, Lu K, Jeavons S, Schapkaitz I, Anderson-Hunt M, Bush AI (2008). N-acetyl cysteine for depressive symptoms in bipolar disorder: a double-blind randomized placebo-controlled trial. Biological Psychiatry. — PubMed PMID: 18534556